Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice.

Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, Lu S, Jiang XC.

J Biol Chem. 2005 Mar 18;280(11):10284-9. Epub 2004 Dec 6.

2.

Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate.

Kihara A, Mitsutake S, Mizutani Y, Igarashi Y.

Prog Lipid Res. 2007 Mar;46(2):126-44. Epub 2007 Mar 14. Review.

PMID:
17449104
3.

Principles of bioactive lipid signalling: lessons from sphingolipids.

Hannun YA, Obeid LM.

Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50. doi: 10.1038/nrm2329. Review.

PMID:
18216770
4.

Sphingolipids: major regulators of lipid metabolism.

Worgall TS.

Curr Opin Clin Nutr Metab Care. 2007 Mar;10(2):149-55. Review.

PMID:
17285002
5.
6.

Sphingomyelin metabolites in vascular cell signaling and atherogenesis.

Augé N, Nègre-Salvayre A, Salvayre R, Levade T.

Prog Lipid Res. 2000 May;39(3):207-29. Review.

PMID:
10799716
7.

Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology.

Merrill AH Jr, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, Riley RT, Voss KA, Wang E.

Toxicol Appl Pharmacol. 1997 Jan;142(1):208-25. Review.

PMID:
9007051
8.

Enzymes of sphingolipid metabolism: from modular to integrative signaling.

Hannun YA, Luberto C, Argraves KM.

Biochemistry. 2001 Apr 24;40(16):4893-903. Review.

PMID:
11305904
9.

Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption.

Linn SC, Kim HS, Keane EM, Andras LM, Wang E, Merrill AH Jr.

Biochem Soc Trans. 2001 Nov;29(Pt 6):831-5. Review.

PMID:
11709083
10.

[Arteriosclerosis--the mutual contribution of the arterial wall cells and serum lipids].

Bar-On H, Stein Y.

Harefuah. 1972 Mar 1;82(5):221-3. Review. Hebrew. No abstract available.

PMID:
4559492
11.
12.

[Sphingolipid and apoptosis].

Wang J, Hu XS, Shi JP.

Sheng Li Ke Xue Jin Zhan. 2003 Jul;34(3):217-21. Review. Chinese.

PMID:
14628466
13.

Sphingolipids in inflammation: pathological implications and potential therapeutic targets.

Nixon GF.

Br J Pharmacol. 2009 Oct;158(4):982-93. doi: 10.1111/j.1476-5381.2009.00281.x. Epub 2009 Jun 25. Review.

14.

Sphingolipids in mammalian cell signalling.

Ohanian J, Ohanian V.

Cell Mol Life Sci. 2001 Dec;58(14):2053-68. Review.

PMID:
11814056
15.

Sphingolipid metabolism and atherosclerosis.

Jiang XC, Liu J.

Handb Exp Pharmacol. 2013;(216):133-46. doi: 10.1007/978-3-7091-1511-4_7. Review.

PMID:
23563655
16.

Beyond a structural component: sphingolipids in immunology.

Prieschl EE, Baumruker T.

Arch Immunol Ther Exp (Warsz). 2000;48(3):163-71. Review.

PMID:
10912620
17.

Regulation of de novo sphingolipid biosynthesis by the ORMDL proteins and sphingosine kinase-1.

Siow D, Sunkara M, Morris A, Wattenberg B.

Adv Biol Regul. 2015 Jan;57:42-54. doi: 10.1016/j.jbior.2014.09.002. Epub 2014 Sep 17. Review.

PMID:
25319495
18.

Sphingolipid metabolism and its role in the skeletal tissues.

Khavandgar Z, Murshed M.

Cell Mol Life Sci. 2015 Mar;72(5):959-69. doi: 10.1007/s00018-014-1778-x. Epub 2014 Nov 26. Review.

PMID:
25424644
19.

Sphingolipids related to apoptosis from the point of view of membrane structure and topology.

van Blitterswijk WJ, van der Luit AH, Caan W, Verheij M, Borst J.

Biochem Soc Trans. 2001 Nov;29(Pt 6):819-24. Review.

PMID:
11709081
20.

Diet and atherosclerosis in apolipoprotein E-deficient mice.

Imaizumi K.

Biosci Biotechnol Biochem. 2011;75(6):1023-35. Epub 2011 Jun 13. Review.

Supplemental Content

Support Center